Transitions in D&D Management
We thank Dr. Wierzba for his hard work and commitment to IVI, and we wish him all the best in his new endeavours.
IVI is pleased to announce that his successor will be Dr. Laura Digilio who will join IVI as Interim Director of Development & Delivery, effective January 1, 2015. Dr. Digilio brings a wealth of experience and knowledge in various vaccines and clinical development. Her most recent position was Senior Director, Clinical Development and HIV and Polio Vaccine Programs Clinical Leader at Crucell (now Janssen Vaccines) in Leiden, The Netherlands. Her prior positions include Senior Cluster Physician, Meningitis Cluster, Clinical R&D, Novartis Vaccines in Siena, Italy; and Associate Director Rotavirus, MMRV Vaccines, Clinical Research, Merck Research Laboratories in West Point, PA. She received her MD from the University of Naples Medical School in Naples, Italy, and conducted her postgraduate fellowship and training as: a postdoctoral fellow with Dr. Robert Grant, Gladstone Institute of Virology and Immunology, University of California at San Francisco; a visiting fellow in the laboratory of Dr. Robert Gallo, National Cancer Institute, National Institutes of Health, Bethesda, MD; and a resident in Infectious Diseases and post-graduate researcher at the Clinic of Infectious Diseases, University of Naples Medical School, Naples, Italy.
Dr. Digilio will visit IVI between now and the end of the year to work with Dr. Wierzba and the D&D team on the transition.